

Head and Neck Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0 __I __II __III __IVA __IVB __IVC __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Second Line+

ECOG Performance Status: __ 0 __ 1 __2 __3 __4

Hypopharynx and larynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol) * with concurrent radiation therapy (RT)

Hypopharynx and larynx: candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT), followed by adjuvant therapy

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary : candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Nasopharynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT) followed by adjuvant therapy

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT), followed by adjuvant therapy

Nasopharynx | Metastatic and recurrent disease | First Line and subsequent lines of therapy (1st line+) | Performance Status 0,1,2

Cisplatin (Platinol)** and fluorouracil (5FU)

Cisplatin (Platinol)** and gemcitabine (Gemzar)

Cisplatin (Platinol)** and paclitaxel (Taxol)

Cisplatin (Platinol) or carboplatin (Paraplatin) (single agent)

Gemcitabine (Gemzar)

Methotrexate

Paclitaxel (Taxol)

*High dose cisplatin is defined as weekly dosing to achieve 200-300 mg/m² total cisplatin dose

**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

Head and Neck Cancer Pathways

(Continued)

Non-Nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | First Line | Performance Status 0,1,2

___ Carboplatin (Paraplatin), fluorouracil (5FU), and cetuximab (Erbix)

___ Cisplatin (Platinol), fluorouracil (5FU), and cetuximab (Erbix)

Non-nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | Second Line and Subsequent lines of therapy | Performance Status 0,1,2

___ Fluorouracil (5FU)

___ Methotrexate

___ Nivolumab (Opdivo)

___ Paclitaxel (Taxol)

*High dose cisplatin is defined as weekly dosing to achieve 200-300 mg/m² total cisplatin dose

**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

